Metabolism in vivo of 3,4,5,3',4'-pentachlorobiphenyl (PenCB) and toxicological assessment of the metabolite were investigated using male Wistar rats. Only one metabolite was isolated from the feces of rats administered 3,4,5,3',4'-PenCB. By gas chromatography-mass spectrometry, the methylated metabolite was identified with the synthesized authentic sample, 4'-methoxy-3,4,5,3',5'-PenCB. This indicated that the metabolite was 4'-hydroxy-3,4,5,3',5'-PenCB, which was produced via a 4',5'-epoxide formation and subsequent NIH-shift of the 4'-chlorine to the 5'-position. Administration of the metabolite at either single i.p. dose of 3 or 10 mg/kg to rats did not cause any toxic and biological effects such as body weight loss, atrophy of thymus and spleen, liver hypertrophy, increase of liver lipids, or 3-methylcholanthrene-type induction of liver enzymes. These changes were observed in rats administered with 3,4,5,3',4'-PenCB at a single dose of 3 mg/kg. In addition, a trace amount of 4'-hydroxy-3,4,5,3',5'-PenCB could be detected in rat liver 5 d after treatment with 3,4,5,3',4'-PenCB or 4'-hydroxy-3,4,5,3',5'-PenCB. The amount of this metabolite excreted in feces during 5 d after treatment with 3,4,5,3',4'-PenCB accounted for only 1.3% of dose. In 4'-hydroxy-3,4,5,3',5'-PenCB-treated rats, about 60% of dose was excreted as unchanged in feces for 5 d. These results suggest that this metabolite is a detoxified product and has no longer the high affinity for the liver, being excreted rapidly into the feces.
No takes yet. Share an insight, caveat, or question.
Koga et al. (1990) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: